Medscape is available in 5 Language Editions – Choose your Edition here.



  • Author: Frances M Dyro, MD; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
Updated: May 21, 2014


Organophosphates (OPs) are chemical substances originally produced by the reaction of alcohols and phosphoric acid. In the 1930s, organophosphates were used as insecticides, but the German military developed these substances as neurotoxins in World War II. They function as cholinesterase inhibitors, thereby affecting neuromuscular transmission.

Organophosphate insecticides, such as diazinon, chlorpyrifos, disulfoton, azinphos-methyl, and fonofos, have been used widely in agriculture and in household applications as pesticides. Over 25,000 brands of pesticides are available in the United States, and their use is monitored by the Environmental Protection Agency (EPA).

Diazinon was sold in the United States for 48 years with 14.7 million pounds sold annually. It was the most widely used ingredient in lawn and garden sprays in the United States. Diazinon was found under the brand names Real Kill, Ortho, and Spectracide. In the past decade, the EPA reached an agreement with the pesticide industry to end the production of diazinon by March 2001 for indoor use and June 2003 for lawn and garden use. Chlorpyrifos (Dursban) was involved in a negotiated phaseout in June 2000. These phaseouts resulted from recognition of the special risk that these substances posed for children. Four percent of patients presenting to poison control centers report pesticide exposure. Of those patients, 34% are children younger than 6 years.

Toxic nerve agents used by the military are often of the organophosphate group; an example is sarin, the nerve gas used in a terrorist action in Tokyo in 1995. In anticipation of military use of OP neurotoxins during the Gulf War, the US military was given prophylactic agents which some believe caused some of the symptoms of Gulf War syndrome.

With the emergence of the West Nile virus in the northeastern United States, programs of spraying have been implemented in large urban areas, in particular New York's Central Park.

Controversy exists regarding the long-term effects of exposure to low levels of potentially neurotoxic substances.[1]

Therapeutic uses of organophosphates

Several organophosphate agents are being tried therapeutically. Cholinesterase inhibition, which in large doses makes these agents effective pesticides, also may be useful in other doses for treating dementia. Metrifonate has been used to treat schistosomiasis and is undergoing trials for the treatment of primary degenerative dementia.

The organophosphates pyridostigmine and physostigmine are carbamate anticholinesterases that have been used for many years for the treatment of myasthenia gravis. Although the short-duration anticholinesterases are generally safe, reports of their abuse are associated with a picture similar to pesticide intoxication.

One of the author's patients had been diagnosed erroneously as a myasthenic. Long-term "therapeutic" doses of physostigmine chemically altered her neuromuscular junctions to the point where she had to be slowly weaned from the drug.

Sung and others have reported on the ability of these substances to induce nicotinic receptor modulation.[2] This explains the action of these drugs and may result in development of more effective agents.

Historic and new uses of organophosphates

The first organophosphate was synthesized in 1850. Physostigmine was used to treat glaucoma in the 1870s. By the 1930s, synthetic cholinesterase inhibitors were being used for skeletal muscle and autonomic disorders. Some organophosphates were tried in the treatment of parkinsonism.

In 1986, testing began for tacrine, the first cholinesterase inhibitor to be tried for Alzheimer disease; it was released for clinical use in 1993. It is no longer in use. The blood-brain barrier has been the limiting factor in developing a cholinesterase inhibitor for use in dementia. Drugs such as rivastigmine are now widely used. Reported adverse effects are nausea and vomiting, with resultant weight loss because of the increase in cholinergic activity. It has been shown to be useful in mild to moderately severe Alzheimer disease.

Pyridostigmine has been tried for the fatigue of postpolio syndrome but showed no benefit.[3]



The mechanism of action, on both target and nontarget species, is irreversible inhibition of acetylcholinesterase (AchE). Acetylcholinesterase is found in red blood cells and in nicotinic and muscarinic receptors in nerve, muscle, and gray matter of the brain. Plasma acetylcholinesterase is found in CNS white matter, pancreas, and heart. It is a hepatic acute phase protein that often is decreased in liver dysfunction, malnutrition, neoplastic disease, pregnancy, and infectious processes as well as in narcotic or cocaine use. Decrease in plasma cholinesterase results in a decrease of cholinesterase activity in the central, parasympathetic, and sympathetic nervous systems.

Organophosphates phosphorylate the serine hydroxyl group at the site of action of acetylcholine. They bind irreversibly, deactivating the esterase, resulting in accumulation of acetylcholine at the endplate. Accumulation of acetylcholine at the neuromuscular junction causes persistent depolarization of skeletal muscle, resulting in weakness and fasciculations. In the central nervous system, neural transmission is disrupted. If this block is not reversed by a strong nucleophile such as pralidoxime (2-PAM) within 24 hours, large amounts of acetylcholinesterase are destroyed. RBC cholinesterase levels rise slowly; about 0.5-1% a day.

Delayed neurotoxicity

Delayed neurotoxicity is produced by certain organophosphorus esters classified as axonopathic. Few of the thousands of organophosphorus agents in the market have been associated with delayed onset of neuropathy. In those that produce neuropathy, effects may result from a single large dose or cumulative doses. Organophosphorus ester-induced delayed neuropathy (OPIDN) takes at least 10 days to develop following a single acute exposure. The effects of cumulative doses occur over a period of weeks following exposure.

Pathologic examination reveals central-peripheral distal axonopathy. Typically, the spinal cord tracts and distal axons of the lower extremities are involved more than the upper extremities. Primary axonopathy is accompanied by secondary demyelination. Sensory and motor fibers are involved. Interestingly, this late toxicity is not a result of acetylcholinesterase inhibition but rather a result of phosphorylation of a receptor protein, neurotoxic esterase, also called neuropathy target esterase (NTE). The exact mechanism is not known.[4]

Lotti et al described a second step, an "aging" of the phosphoryl-enzyme complex, that is required to produce the neurotoxic effect.[1] Not all organophosphates cause delayed neuropathy. An in vitro test measuring the catalytic activity of this neuron-specific enolase (ie, neuropathy target esterase) may be able to determine the risk of development of delayed neuropathy. Studies in hens given single doses of diazinon or triorthocresyl phosphate (TOCP), showed a "dying back" type of lesion that developed in hens exposed to TOCP but not those exposed to diazinon. Peripheral nerves were affected, and researchers noted moderately severe to marked degeneration of the folia of the cerebellum, the medulla, and spinal cord (the dorsolateral and dorsal columns). TOCP is not a cholinesterase inhibitor.[4]




United States

In 1983, the rate of mortality from unintentional pesticide poisoning was 2.7 per 10 million men and 0.5 per 10 million women. Generally, about 20,000 cases of organophosphate intoxication are reported yearly. About 2.3-2.6 per 10 million of the cases represent suicidal ingestion. In 1998, American Association of Poison Control Centers reported 16,392 exposures to organophosphates, with 11 reported deaths. The true number of exposures is likely to be underestimated. Most cases of cumulative exposure in agricultural workers go unreported.


Estimating the number of individuals exposed to organophosphates internationally is virtually impossible. Many agents considered too toxic to market in the United States still may be available in developing nations. Thirty percent of the pesticides exported from the United States are banned for use in the United States. Awareness of the dangers of pesticides is less in developing countries. The number of children exposed is likely to be greater in developing countries where children are expected to work on the family farm or may be hired out as laborers. The use of pesticides as agents of suicide is far more common in developing nations. Eddleston et al (2008) estimate that in the developing world, organophosphorus pesticide self-poisoning kills 200,000 people a year.[5]


Mortality rate is generally low in patients treated promptly. Morbidity involves the late onset of neuropathy and tremor, and in large doses, convulsions and delirium. Other late effects are less expected. Compston et al reported reduced bone formation after exposure to organophosphates in 80 male agricultural workers. The mechanism of action was thought to be inhibition of acetylcholinesterase in bone matrix. Acetylcholinesterase is expressed by osteoblasts; it is present along cement lines and in osteoid. The author believes that acetylcholinesterase may have a role in the regulation of cell-matrix interactions and in the coupling of bone resorption and formation.[6]

Frequently, the cumulative effects of low doses of organophosphates are neuropsychological. A joint report by the UK Royal College of Physicians and Psychiatrists concluded that a wide range of often-severe symptoms such as excessive fatigue, poor concentration, and suicidal thoughts are reported more frequently in populations exposed repeatedly. Exposed individuals often have a chronic flulike state that improves when exposure ceases. A patient the author saw 3 years after exposure to a single high dose of diazinon was left with significant cognitive impairment and episodes of generalized muscle hypertonia, initially thought to be seizural. Chronic neuropsychological effects have been seen in 4-9% of patients exposed in occupation-related use.[7, 8, 9]


No particular racial susceptibility to organophosphate toxicity has been noted, but the reported incidence is 3-fold greater in African Americans. This may be a result of the predominance of African Americans in the at-risk population.

Menegon et al studied the possibility of genetic predisposition in patients who developed Parkinson disease after pesticide exposure. Glutathione transferase polymorphism was investigated. Glutathione transferase polymorphism 1 (GSTP1) genotypes appeared to be associated with the risk.[10]

Studies by Bhatt et al may confirm the existence of genetic susceptibility. The risk of developing Parkinson disease after long-term pesticide exposure has been reported. Bhatt et al reported 5 cases of acute and reversible parkinsonism due to organophosphate pesticide exposure in India. One patient was a 31-year-old woman who ingested an organophosphate pesticide in a suicide attempt. The other 4 were exposed following household use of pesticides. Typical features of parkinsonism developed in all cases; however, the patients did not respond to levodopa-carbidopa administration. All patients improved when they were removed from the source of the toxin. Surprisingly, atropine, which is used to provide protection against the effect of organophosphates, was used to treat parkinsonism prior to the development of more effective agents.[11]


Most cases of exposure involve agricultural workers or those involved in pest control; therefore, most reported cases are males.

  • Susceptibility apparently is not increased inherently among males or females.
  • Inhibition of RBC cholinesterase activity is greater in females than in males.


Age does not appear to be a significant factor, although children exposed to pesticides may absorb relatively more chemical with respect to surface area. Children are also more likely to be exposed to pesticides used in lawn care in the course of play. Exposure to vaporized pesticide in the air, dermal exposure, and placing of pesticide-covered fingers in the mouth increase the routes of exposure.

Contributor Information and Disclosures

Frances M Dyro, MD Associate Professor of Neurology, New York Medical College; Physician, Neuromuscular Section, Department of Neurology, Westchester Medical Center

Frances M Dyro, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Neil A Busis, MD Chief of Neurology and Director of Neurodagnostic Laboratory, UPMC Shadyside; Clinical Professor of Neurology and Director of Community Neurology, Department of Neurology, University of Pittsburgh Physicians

Neil A Busis, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine

Disclosure: Nothing to disclose.

Chief Editor

Stephen A Berman, MD, PhD, MBA Professor of Neurology, University of Central Florida College of Medicine

Stephen A Berman, MD, PhD, MBA is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, Phi Beta Kappa

Disclosure: Nothing to disclose.

Additional Contributors

Jonathan S Rutchik, MD, MPH Associate Clinical Professor, Division of Occupational Medicine, Department of Medicine, University of California, San Francisco, School of Medicine; Neurology, Environmental and Occupational Medicine Associates (

Jonathan S Rutchik, MD, MPH is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, International Parkinson and Movement Disorder Society, Society of Toxicology, Western Occupational and Environmental Medical Association, American College of Occupational and Environmental Medicine

Disclosure: Nothing to disclose.

  1. Lotti M, Becker CE, Aminoff MJ. Organophosphate polyneuropathy: pathogenesis and prevention. Neurology. 1984 May. 34(5):658-62. [Medline].

  2. Sung JJ, Kim SJ, Lee HB, et al. Anticholinesterase induces nicotinic receptor modulation. Muscle Nerve. 1998 Sep. 21(9):1135-44. [Medline].

  3. Trojan DA, Collet JP, Shapiro S, et al. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology. 1999 Oct 12. 53(6):1225-33. [Medline].

  4. Abou-Donia MB. Organophosphorus ester-induced chronic neurotoxicity. Arch Environ Health. 2003 Aug. 58(8):484-97. [Medline].

  5. Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008 Feb 16. 371(9612):597-607. [Medline]. [Full Text].

  6. Compston JE, Vedi S, Stephen AB, et al. Reduced bone formation after exposure to organophosphates. Lancet. 1999 Nov 20. 354(9192):1791-2. [Medline].

  7. Alavanja MC, Hoppin JA, Kamel F. Health effects of chronic pesticide exposure: cancer and neurotoxicity. Annu Rev Public Health. 2004. 25:155-97. [Medline].

  8. Eskenazi B, Maizlish NA. Effects of Occupational Exposure to Chemicals on Neurobehavioral Functioning. Tarter RE, Thiel DHV, Edwards KL, eds. Medical Neuropsychology: The Impact of Disease on Behavior. New York, NY: Plenum Press; 1988.

  9. Rosenstock L, Keifer M, Daniell WE, et al. Chronic central nervous system effects of acute organophosphate pesticide intoxication. The Pesticide Health Effects Study Group. Lancet. 1991 Jul 27. 338(8761):223-7. [Medline].

  10. Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet. 1998 Oct 24. 352(9137):1344-6. [Medline].

  11. Bhatt MH, Elias MA, Mankodi AK. Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases. Neurology. 1999 Apr 22. 52(7):1467-71. [Medline].

  12. Himuro K, Murayama S, Nishiyama K, et al. Distal sensory axonopathy after sarin intoxication. Neurology. 1998 Oct. 51(4):1195-7. [Medline].

  13. Senanayake N, Jeyaratnam J. Toxic polyneuropathy due to gingili oil contaminated with tri-cresyl phosphate affecting adolescent girls in Sri Lanka. Lancet. 1981 Jan 10. 1(8211):88-9. [Medline].

  14. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med. 1987 Mar 26. 316(13):761-3. [Medline].

  15. Morgan JP, Penovich P. Jamaica ginger paralysis. Forty-seven-year follow-up. Arch Neurol. 1978 Aug. 35(8):530-2. [Medline].

  16. Rajapakse BN, Thiermann H, Eyer P, Worek F, Bowe SJ, Dawson AH, et al. Evaluation of the Test-mate ChE (cholinesterase) field kit in acute organophosphorus poisoning. Ann Emerg Med. 2011 Dec. 58(6):559-564.e6. [Medline].

  17. Maselli RA, Soliven BC. Analysis of the organophosphate-induced electromyographic response to repetitive nerve stimulation: paradoxical response to edrophonium and D-tubocurarine. Muscle Nerve. 1991 Dec. 14(12):1182-8. [Medline].

  18. Rutchik JS, Rutkove SB. Effect of temperature on motor responses in organophosphate intoxication. Muscle Nerve. 1998 Jul. 21(7):958-60. [Medline].

  19. De Luca CJ, Buccafusco JJ, Roy SH, et al. The electromyographic signal as a presymptomatic indicator of organophosphates in the body. Muscle Nerve. 2006. 33(3):369-76. [Medline].

  20. Singh G, Sidhu UP, Mahajan R, et al. Phrenic nerve conduction studies in acute organophosphate poisoning. Muscle Nerve. 2000 Apr. 23(4):627-32. [Medline].

  21. Pawar KS, Bhoite RR, Pillay CP, Chavan SC, Malshikare DS, Garad SG. Continuous pralidoxime infusion versus repeated bolus injection to treat organophosphorus pesticide poisoning: a randomised controlled trial. Lancet. 2006 Dec 16. 368(9553):2136-41. [Medline].

  22. Feldman RG. Organophosphates. Occupational and Environmental Neurotoxicology. Philadelphia, Pa: Lippincott-Raven; 1998.

  23. Grandjean P, Landrigan PJ. Developmental neurotoxicity of industrial chemicals. Lancet. 2006 Dec 16. 368(9553):2167-78. [Medline].

  24. Kamel F, Engel LS, Gladen BC, et al. Neurologic symptoms in licensed private pesticide applicators in the agricultural health study. Environ Health Perspect. 2005 Jul. 113(7):877-82. [Medline].

  25. Ludomirsky A, Klein HO, Sarelli P, et al. Q-T prolongation and polymorphous ("torsade de pointes") ventricular arrhythmias associated with organophosphorus insecticide poisoning. Am J Cardiol. 1982 May. 49(7):1654-8. [Medline].

  26. Maddy KT, Edmiston S, Richmond D. Illness, injuries, and deaths from pesticide exposures in California 1949-1988. Rev Environ Contam Toxicol. 1990. 114:57-123. [Medline].

  27. Savage EP, Keefe TJ, Mounce LM, et al. Chronic neurological sequelae of acute organophosphate pesticide poisoning. Arch Environ Health. 1988 Jan-Feb. 43(1):38-45. [Medline].

  28. Taylor P. Development of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease. Neurology. 1998 Jul. 51(1 Suppl 1):S30-5; discussion S65-7. [Medline].

  29. Tune LE, Damlouji NF, Holland A, et al. Association of postoperative delirium with raised serum levels of anticholinergic drugs. Lancet. 1981 Sep 26. 2(8248):651-3. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.